Study: NCT01099579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir powder
Description: Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir powder
Description: Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir powder
Description: Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution
Description: Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution
Description: Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution
Description: Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir capsules
Description: Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir capsules
Description: Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir capsules
Description: Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsules
Description: Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsules
Description: Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsules
Description: Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.